This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Figure 1
EQ-5D questionnaire events – (A) clinical definition of cardiotoxicity; (B) clinical indication for cardioprotective therapy initiation; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 2
EQ-5D questionnaire events – traditional cardiac imaging modality metrics: (A) ECHO LVEF – echocardiographic left ventricular ejection fraction; (B) CMR LVEF – traditional cardiac magnetic resonance left ventricular ejection fraction; (C) MYOSTRAIN LVEF – fast strain-encoded cardiac magnetic resonance left ventricular ejection fraction; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 3
EQ-5D questionnaire events – myocardial strain imaging modality metrics: (A) ECHO GLS – echocardiographic global longitudinal strain; (B) CMR GLS – traditional cardiac magnetic resonance global longitudinal strain; (C) MYOHEALTH, (D) FUNCTIONAL MYOSTRAIN, (E) MYOSTRAIN ≤-11 and (F) MYOSTRAIN ≤-12 – percent of left ventricle longitudinal and circumferential fast strain-encoded cardiac magnetic resonance segments with normal, functional, ≤-11% or ≤-12% strain, respectively; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 4
SF-36 physical component questionnaire events – (A) clinical definition of cardiotoxicity; (B) clinical indication for cardioprotective therapy initiation; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 5
SF-36 physical component questionnaire events – traditional cardiac imaging modality metrics: (A) ECHO LVEF – echocardiographic left ventricular ejection fraction; (B) CMR LVEF – traditional cardiac magnetic resonance left ventricular ejection fraction; (C) MYOSTRAIN LVEF – fast strain-encoded cardiac magnetic resonance left ventricular ejection fraction; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 6
SF-36 physical component questionnaire events – myocardial strain imaging modality metrics: (A) ECHO GLS – echocardiographic global longitudinal strain; (B) CMR GLS – traditional cardiac magnetic resonance global longitudinal strain; (C) MYOHEALTH, (D) FUNCTIONAL MYOSTRAIN, (E) MYOSTRAIN ≤-11 and (F) MYOSTRAIN ≤-12 – percent of left ventricle longitudinal and circumferential fast strain-encoded cardiac magnetic resonance segments with normal, functional, ≤-11% or ≤-12% strain, respectively; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 7
SF-36 mental component questionnaire events – (A) clinical definition of cardiotoxicity; (B) clinical indication for cardioprotective therapy initiation; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 8
SF-36 mental component questionnaire events – traditional cardiac imaging modality metrics: (A) ECHO LVEF – echocardiographic left ventricular ejection fraction; (B) CMR LVEF – traditional cardiac magnetic resonance left ventricular ejection fraction; (C) MYOSTRAIN LVEF – fast strain-encoded cardiac magnetic resonance left ventricular ejection fraction; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 9
SF-36 mental component questionnaire events – myocardial strain imaging modality metrics: (A) ECHO GLS – echocardiographic global longitudinal strain; (B) CMR GLS – traditional cardiac magnetic resonance global longitudinal strain; (C) MYOHEALTH, (D) FUNCTIONAL MYOSTRAIN, (E) MYOSTRAIN ≤-11 and (F) MYOSTRAIN ≤-12 – percent of left ventricle longitudinal and circumferential fast strain-encoded cardiac magnetic resonance segments with normal, functional, ≤-11% or ≤-12% strain, respectively; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.